Healthy Volunteers Clinical Trial
Official title:
Effets de la tDCS Sur la Performance Sportive de 2 Profils d'athlètes : Explosifs (Sauteurs de Haut Niveau et Amateur) et Endurants (Cyclistes de Haut Niveau et Amateur)
The study aims to compare the effects of tDCS applied on the dorsolateral prefrontal cortex (dlPFC) vs sham on the neuromuscular system. Two types of athletes will benefit from stimulation: jumper and cyclists. Short and long term effects are assesed by electromyographic records, experimental tasks and self-rated scales.
Transcranial direct current stimulation is a technique of noninvasive brain stimulation which
delivers a electrical current to the scalp to modulate the neuronal activity. Depending on
the polarity of stimulation, tDCS induces a neural hyperexcitability (with anode) or
hypoexcitability (with cathode) of the target area.
Due to its neuromodulatory action, ease of use and low safety, tDCS can be used as a
potential treatment but also as an investigative tool in neurophysiology. Thus, studies have
shown a beneficial effect of tDCS on cognitive and motor functions. Nevertheless, studies
conducted on motor performance and the reduction of neuromuscular fatigue show disparate
results. It is impossible to conclude whether tDCS allows for improved performance and is a
means of doping.
With a prospective, sham-controlled, crossover, double-blind design, this study aims to
evaluate the effect of tDCS on neuromuscular fatigue resistance during explosive (jumping)
and endurance (cycling) exertion.
This study is divided into two parts:
- Part A: jumping group
- Part B: cycling group.
During Part A, participants visit the laboratory on 3 occasions. Each visit is organized in
the same way and is at least 48 hours apart from the previous one.
Participants are divided into two groups according to their level of experience (amateurs vs.
high level).
Before the session of tDCS, participants carry out a psychometric assessment (MCQ, BIS10) and
experimental tasks (BART, EEFRT, STROOP test and Go NoGo task). Then, they performed three
types of jumps (long jump, squat jump and countermovement jump). Finally, participants
benefit from neuromuscular tests (EMG recording of plantar flexor muscle activity,
percutaneous stimulation of the posterior tibial nerve).
Subjects will be submitted to three sessions of tDCS (2 actives and one sham), one by visit,
in the order of randomization. Current intensity will be of 2 mA (or 0 mA), through 25 cm²
surface electrodes, during 20 minutes. The positioning of the stimulation electrodes will be
carried out in compliance with EEG 10/20 standards:
- Sequence order determined by randomization:
1. Anode: F3 / Cathode: AF8/ Stimulation intensity: 2 mA
2. Anode: F3/ Cathode: AF8/ Stimulation intensity: 0 mA
3. Anode: FC2/ Cathode: Left shoulder/ Stimulation intensity: 2 mA
Immediately after the stimulation, participants perform motor and cognitive task again and
the results are compared.
During part B, subjects participate in two training sessions of five days each. The training
sessions are one month apart.
Participants are divided into three groups according to their level of experience (amateurs
vs. high level vs. sedentary).
Each day, the subjects perform two twenty-minute time trials during which they receive a
session of tDCS. (one week with the active tDCS, one week with the sham). So, subjects will
be submitted to 10 tDCS stimulation sessions (active or sham) for five consecutive days (2
sessions of 20 minutes/day). Current intensity will be of 2 mA, through 25 cm² surface
electrodes, placed over the dlPFC and the supraorbital region (anode position over F3 and
cathode over AF8, according to the EEG 10-20 international system).
At J1 and J5 of each session (before and after session training), subjects carry out a
psychometric assessment (MCQ, BIS10) and experimental tasks (BART, EEFRT, STROOP test and Go
NoGo task) and benefit from neuromusculars tests (EMG recording of plantar flexor muscle
activity, percutaneous stimulation of the posterior tibial nerve). Baseline measures will be
compared to those obtained immediately after the end of sessions (5 days: short-term
effects), and to 12 and 30 days later (long-term effects). Active and sham stimulation
sessions outcomes will as well be compared.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |